JP6692293B2 - Ｃｎｓにおける酵素活性を増大するための方法および組成物 - Google Patents

Ｃｎｓにおける酵素活性を増大するための方法および組成物 Download PDF

Info

Publication number
JP6692293B2
JP6692293B2 JP2016529759A JP2016529759A JP6692293B2 JP 6692293 B2 JP6692293 B2 JP 6692293B2 JP 2016529759 A JP2016529759 A JP 2016529759A JP 2016529759 A JP2016529759 A JP 2016529759A JP 6692293 B2 JP6692293 B2 JP 6692293B2
Authority
JP
Japan
Prior art keywords
sgsh
amino acid
fusion antibody
fusion
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016529759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525545A (ja
JP2016525545A5 (enExample
Inventor
ウィリアム・エム・パードリッジ
ルーベン・ジェイ・ボアド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Armagen Inc
Original Assignee
Armagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armagen Inc filed Critical Armagen Inc
Publication of JP2016525545A publication Critical patent/JP2016525545A/ja
Publication of JP2016525545A5 publication Critical patent/JP2016525545A5/ja
Priority to JP2020072208A priority Critical patent/JP6914392B2/ja
Application granted granted Critical
Publication of JP6692293B2 publication Critical patent/JP6692293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016529759A 2013-07-22 2014-05-19 Ｃｎｓにおける酵素活性を増大するための方法および組成物 Active JP6692293B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020072208A JP6914392B2 (ja) 2013-07-22 2020-04-14 Ｃｎｓにおける酵素活性を増大するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361857140P 2013-07-22 2013-07-22
US61/857,140 2013-07-22
PCT/US2014/038660 WO2015012944A1 (en) 2013-07-22 2014-05-19 Methods and compositions for increasing enzyme activity in the cns

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020072208A Division JP6914392B2 (ja) 2013-07-22 2020-04-14 Ｃｎｓにおける酵素活性を増大するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2016525545A JP2016525545A (ja) 2016-08-25
JP2016525545A5 JP2016525545A5 (enExample) 2017-06-29
JP6692293B2 true JP6692293B2 (ja) 2020-05-13

Family

ID=51023055

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016529759A Active JP6692293B2 (ja) 2013-07-22 2014-05-19 Ｃｎｓにおける酵素活性を増大するための方法および組成物
JP2020072208A Active JP6914392B2 (ja) 2013-07-22 2020-04-14 Ｃｎｓにおける酵素活性を増大するための方法および組成物
JP2021115534A Pending JP2021180658A (ja) 2013-07-22 2021-07-13 Ｃｎｓにおける酵素活性を増大するための方法および組成物
JP2023153971A Pending JP2024012225A (ja) 2013-07-22 2023-09-20 Ｃｎｓにおける酵素活性を増大するための方法および組成物
JP2024230169A Pending JP2025041923A (ja) 2013-07-22 2024-12-26 Ｃｎｓにおける酵素活性を増大するための方法および組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020072208A Active JP6914392B2 (ja) 2013-07-22 2020-04-14 Ｃｎｓにおける酵素活性を増大するための方法および組成物
JP2021115534A Pending JP2021180658A (ja) 2013-07-22 2021-07-13 Ｃｎｓにおける酵素活性を増大するための方法および組成物
JP2023153971A Pending JP2024012225A (ja) 2013-07-22 2023-09-20 Ｃｎｓにおける酵素活性を増大するための方法および組成物
JP2024230169A Pending JP2025041923A (ja) 2013-07-22 2024-12-26 Ｃｎｓにおける酵素活性を増大するための方法および組成物

Country Status (6)

Country Link
US (3) US20150023956A1 (enExample)
EP (2) EP3024848B1 (enExample)
JP (5) JP6692293B2 (enExample)
AU (2) AU2014293626A1 (enExample)
CA (1) CA2918579C (enExample)
WO (1) WO2015012944A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007285763B2 (en) 2006-08-18 2011-12-15 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
CA3184105A1 (en) 2007-07-27 2009-02-05 Armagen Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
WO2010108048A2 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
US8486399B2 (en) 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7532338B2 (ja) * 2018-08-07 2024-08-13 アーマジェン・インコーポレイテッド ヘキソサミニダーゼａ、酸スフィンゴミエリナーゼおよびパルミトイル－タンパク質チオエステラーゼ１のｃｎｓにおける活性を増加させるための方法および組成物
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
KR20230156889A (ko) * 2022-05-04 2023-11-15 이뮤노포지 주식회사 GLP-1, 면역글로불린 Fc, 및 IGF-1을 포함하는 융합단백질 및 이의 용도
WO2023240220A1 (en) * 2022-06-09 2023-12-14 The University Of North Carolina At Chapel Hill Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
TW279133B (enExample) 1990-12-13 1996-06-21 Elan Med Tech
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US6060069A (en) 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US6195608B1 (en) 1993-05-28 2001-02-27 Lucent Technologies Inc. Acoustic highway monitor
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
US5656284A (en) 1995-04-24 1997-08-12 Balkin; Michael S. Oral transmucosal delivery tablet and method of making it
CN1137680C (zh) 1995-09-19 2004-02-11 藤泽药品工业株式会社 气雾剂组合物
JP2002505576A (ja) * 1997-05-30 2002-02-19 アムジエン・インコーポレーテツド 神経栄養因子レセプター
US6016800A (en) 1997-10-24 2000-01-25 Century; Theodore J. Intrapulmonary aerosolizer
DK1037687T3 (da) 1997-12-11 2009-01-26 Alza Corp Anordning til at forbedre et middels transdermale strömning
US6348210B1 (en) 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6284262B1 (en) 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
CN110496230A (zh) * 2003-02-11 2019-11-26 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
AU2003286870A1 (en) * 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
JP2013507131A (ja) * 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
JP6073783B2 (ja) * 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
CN103443125B (zh) * 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
US9206401B2 (en) * 2010-12-22 2015-12-08 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
US8486399B2 (en) * 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US20130323221A1 (en) * 2012-05-30 2013-12-05 Biostrategies LC Plant lectins as carriers of associated drug substances into animal and human cells

Also Published As

Publication number Publication date
CA2918579C (en) 2023-01-03
JP2016525545A (ja) 2016-08-25
JP2020171284A (ja) 2020-10-22
JP2024012225A (ja) 2024-01-26
CA2918579A1 (en) 2015-01-29
AU2020200250A1 (en) 2020-02-06
US20220348672A1 (en) 2022-11-03
EP3024848B1 (en) 2020-07-08
WO2015012944A1 (en) 2015-01-29
US20200308292A1 (en) 2020-10-01
AU2014293626A1 (en) 2016-02-18
EP3024848A1 (en) 2016-06-01
US20150023956A1 (en) 2015-01-22
JP6914392B2 (ja) 2021-08-04
JP2021180658A (ja) 2021-11-25
EP3730516A1 (en) 2020-10-28
JP2025041923A (ja) 2025-03-26

Similar Documents

Publication Publication Date Title
US20240327507A1 (en) Methods and compositions for increasing iduronate 2-sulfate activity in the cns
JP6914392B2 (ja) Ｃｎｓにおける酵素活性を増大するための方法および組成物
US20240409650A1 (en) Methods and compositions for increasing n-acetylglucosaminidase activity in the cns
US8974791B2 (en) Methods and compositions for increasing α-L-iduronidase activity in the CNS
US20250179201A1 (en) Methods and compositions for increasing galactosidase beta-1 activity in the cns
HK40013772A (en) Methods and compositions for increasing iduronate 2-sulfatase activity in the cns

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200414

R150 Certificate of patent or registration of utility model

Ref document number: 6692293

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250